Journal Of The American Academy Of Dermatology[JOURNAL]

Nukaly HY, Barnawi G, Thalib HI … +10 more , Basamih KA, Khan S, Jamal A, Aljohani AG, Aldien AS, Lazarowitz R, de Alencar EBA, Miller WH, Niaz G, Litvinov IV

J Am Acad Dermatol · 2026 Jun · PMID 42285257 · Publisher ↗

Immune checkpoint inhibitors (ICIs) have markedly advanced oncology by enhancing the immune system's ability to combat malignancies. However, their use is increasingly associated with immune-related adverse events, inclu... Immune checkpoint inhibitors (ICIs) have markedly advanced oncology by enhancing the immune system's ability to combat malignancies. However, their use is increasingly associated with immune-related adverse events, including immunobullous dermatoses. These disorders, such as bullous pemphigoid, pemphigus vulgaris, linear immunoglobulin A bullous dermatosis, mucous membrane pemphigoid, paraneoplastic pemphigus, dermatitis herpetiformis, and lichen planus pemphigoides present significant diagnostic and therapeutic challenges. This clinical review explores the pathogenesis, clinical presentation, diagnosis, and management strategies of immunobullous dermatoses triggered by ICIs, highlighting the complex relationship between effective cancer treatment and immune regulation. ICI-induced immunobullous dermatoses closely mimic their conventional autoimmune counterparts but often have unique clinical considerations, such as delayed onset, mucosal predilection, and persistence post-discontinuation of medication. Diagnostic evaluation relies on clinical suspicion, histopathology, direct and indirect immunofluorescence, and enzyme-linked immunosorbent assays. Management typically involves corticosteroids and immunosuppressants, with biologics such as rituximab, dupilumab and omalizumab reserved for refractory cases. Decisions regarding the continuation of ICIs require individualized assessment, balancing cancer control with autoimmune toxicity. Dermatologic and oncologic teams must navigate dual priorities of mitigating autoimmune toxicity and preserving oncologic benefit.

Get PDF PubMed ↗

Cartilage grafts in nasal alar nasolabial interpolation flap reconstruction: Causality, confounding, and clinical decision-making.

Yan J, Wang J

J Am Acad Dermatol · 2026 May · PMID 42283649 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Effectiveness and safety of hematoporphyrin monomethyl ether-mediated photodynamic therapy versus pulsed dye laser for port-wine stain: A retrospective study.

Li X, Liu L, Diao P … +9 more , Zhang L, Zhang T, Li Y, Han C, Chen H, Wei D, Yu H, Liu Q, Jiang X

J Am Acad Dermatol · 2026 Jun · PMID 42276513 · Publisher ↗

BACKGROUND: Hematoporphyrin monomethyl ether-mediated photodynamic therapy (HMME-PDT) is an emerging treatment for port-wine stain (PWS). OBJECTIVE: To compare the effectiveness and safety of HMME-PDT with pulsed dye las... BACKGROUND: Hematoporphyrin monomethyl ether-mediated photodynamic therapy (HMME-PDT) is an emerging treatment for port-wine stain (PWS). OBJECTIVE: To compare the effectiveness and safety of HMME-PDT with pulsed dye laser (PDL) for PWS on the face and neck. METHODS: A retrospective study was conducted comparing 728 patients treated with HMME-PDT and 655 with PDL. Logistic regression was used to assess effectiveness. An excellent improvement was defined as ≥75% lesion clearance. RESULTS: Before adjustment, 41.5% of patients showed excellent improvement after a median of 2 HMME-PDT sessions and 29.2% after a median of 3 PDL sessions. After adjusting for confounders, the HMME-PDT group was more likely to achieve excellent improvement (odds ratio: 2.90, 95% confidence interval: 2.02-4.15, P < .05) than the PDL group. Effectiveness was primarily influenced by lesion size, thickness, number of treatment sessions, and prior treatment. HMME-PDT showed higher incidences of hyperpigmentation (5.4% vs 1.8%, P < .05) and scarring (3.3% vs 0.5%, P < .05) than PDL. LIMITATIONS: The retrospective design and lack of long-term follow-up. CONCLUSION: HMME-PDT showed superior effectiveness than PDL for treating facial and neck PWS, but it carried a higher risk of hyperpigmentation and scarring.

Get PDF PubMed ↗

Comment on ''The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial''.

Baharuddin B, Handayani L, Akl MM

J Am Acad Dermatol · 2026 Jun · PMID 42276512 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Increased dendritic cell density and altered melanin patterns distinguish melanoma from Nevi on CRFF-OCT: A pilot study toward noninvasive diagnosis.

Polo-Silveira L, Zeidan RB, Dusza SW … +2 more , Marghoob A, Jason Chen CS

J Am Acad Dermatol · 2026 Jun · PMID 42276511 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Reconstitution, Storage, and Infection Outcomes of Botulinum Toxin in Academic Dermatology: A National Survey.

Kang BY, Alam M, Hebert AA … +5 more , Minkis K, Sulewski R, Suozzi KC, Vashi NA, Orringer JS

J Am Acad Dermatol · 2026 Jun · PMID 42276510 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

When Acne Meets Excoriation Disorder: A Dilemma in Adolescent Care.

Gandhi I, Dol N, Bhagia A … +4 more , Fayyad D, Kristensen-Cabrera A, Fishman C, Fishman S

J Am Acad Dermatol · 2026 Jun · PMID 42276509 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Association between baseline total serum IgE and chronic spontaneous urticaria relapse after omalizumab discontinuation.

Hou CY, Chang HC

J Am Acad Dermatol · 2026 Jun · PMID 42276508 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Delayed Surgical Treatment Is Associated with Positive Margins and Worse Long-Term Survival in Early-Stage Vulvar Melanoma: A Retrospective National Cancer Database Study.

Tran HTT, Newcomer JB, Le DV … +4 more , Bakkum-Gamez JN, Lehman JS, Otley CC, Nguyen GH

J Am Acad Dermatol · 2026 Jun · PMID 42270047 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

532 nm KTP laser for treatment of keratosis pilaris rubra: An assessor-blinded, randomized, comparative trial.

Zhou J, Dong X, Chu Y … +3 more , Cai S, Chen X, Xu M

J Am Acad Dermatol · 2026 Jun · PMID 42264386 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Allergens, moisturizing components, and marketing claims of over-the-counter vaginal and vulvar moisturizers: A product analysis.

Khalid H, Maydew E, Nelson-Fuller A … +3 more , Osmani S, Admani S, Murphy E

J Am Acad Dermatol · 2026 Jun · PMID 42264385 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Higher acne risk with injectable compared to transdermal testosterone in transmasculine patients: A retrospective cohort study using the TriNetX database.

Nguyen TQ, Polu D, Cottrell BA … +2 more , Giordano AH, Peebles K

J Am Acad Dermatol · 2026 Jun · PMID 42264384 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

IL-1-Targeted Therapy in Dermatologic Conditions.

Balan K, Elston DM

J Am Acad Dermatol · 2026 Jun · PMID 42264383 · Publisher ↗

Interleukin-1 (IL-1) plays a key role in inflammasome activation, keratinocyte signalling and neutrophil recruitment, and is a driving force behind many neutrophil-rich and suppurative dermatoses. There is robust evidenc... Interleukin-1 (IL-1) plays a key role in inflammasome activation, keratinocyte signalling and neutrophil recruitment, and is a driving force behind many neutrophil-rich and suppurative dermatoses. There is robust evidence supporting the use of IL-1 blockade as a disease-modifying therapy in cryopyrin-associated periodic syndromes and other monogenic periodic fever syndromes, as well as in the treatment of Schnitzler syndrome, where it can rapidly control urticarial and neutrophilic eruptions. Cohort- and series-level data demonstrate high efficacy in IL-1 receptor antagonist deficiency and steroid-refractory pyoderma gangrenosum, whereas benefits appear more heterogeneous in hidradenitis suppurativa, pustular psoriasis and PSTPIP1-associated autoinflammatory diseases. In contrast, conditions such as IL-36 receptor antagonist deficiency, SAPHO syndrome, Sweet syndrome and VEXAS syndrome are supported only by scattered case reports or theoretical rationale, with highly variable or uncertain responses to IL-1 blockade, highlighting the importance of careful clinical and, where possible, genetic phenotyping. We summarise practical considerations for selecting agents, pediatric and adult dosing and safety. IL-1 antagonists are indispensable for a subset of IL-1-driven disorders and represent a rational rescue option for selected neutrophilic dermatoses.

Get PDF PubMed ↗

Ethical challenges in Janus kinase inhibitor access for alopecia areata: When severity thresholds fail to capture disease burden.

Husseinali M, Kannan K, Remé B … +1 more , Tarbox M

J Am Acad Dermatol · 2026 Jun · PMID 42264382 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Response to Wang et al., "Time as a Substantial Confounder in Evaluating Integrated Multidisciplinary Care for Advanced Cutaneous Squamous Cell Carcinoma".

Ran NA, Bapna M, Neff H … +13 more , Waldman A, Cohen JV, Khaddour K, Margalit DN, Tishler RB, Schoenfeld JD, Sethi RK, Rettig EM, Guenette JP, Karn E, Mortelliti C, Silk AW, Ruiz ES

J Am Acad Dermatol · 2026 Jun · PMID 42264381 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Journal Of The American Academy Of Dermatology[JOURNAL]

About